Autolus Therapeutics AUTL 深 沪
等待开盘 09-29 09:30:00 美东时间
1.86
+0.005
+0.27%
华盛通- 最 高1.8899
- 今 开1.82
- 成交量 139.96万股
- 最 低 1.79
- 昨 收 1.855
- 总市值 4.95亿
- 52周最高 2.58
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.175
- 委 比 91.51%
- 总股本 2.66亿
- 历史最高 53.24
- 量 比 0.96
- 振 幅 5.39%
- 历史最低 1.105
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory LN, continues enrolling i...
09-09 19:09
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Autolus Therapeutics' obe-cel has received FDA's RMAT designation for treating SLE and LN, aiming to accelerate its development. The Phase 2 LUMINA trial for refractory LN is ongoing in five countries, with data expected in 2028. Dr. Matthias Will highlighted the significance of this designation in addressing unmet needs for severe autoimmune diseases.
09-09 11:00
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-12 00:57
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported Q2 2026 net product revenue of $45.7 million for AUCATZYL®, up 119% YoY, with FY 2026 guidance raised to $140-$150 million. Gross margin improved due to higher volumes and cost reduction initiatives. The company secured a $250 million credit facility, with $75 million funded. Obe-cel clinical trials are progressing in lupus nephritis, pediatric ALL, and progressive MS. CEO Dr. Christian Itin highlighted strong adopti...
08-11 11:00
Autolus Therapeutics Q2 2026 Earnings Preview
Autolus Therapeutics (AUTL) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. The consensus EPS Estimate is -$0.19 (-5.6% Y/Y) and the consensus Revenue Estimat...
08-10 23:00
美股牛股 | Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股
Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股；AAOI升逾16%，英伟达官宣CPO步入量产提振板块>>
08-04 19:06
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.
08-03 20:52
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million Capital base strengthened through five-year, interest-only credit facilit...
08-03 19:20
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Autolus Therapeutics reported preliminary Q2 2026 AUCATZYL net product revenue of ~$45M with a year-to-date gross margin of ~35%. FY 2026 sales guidance was raised to $140–$150M. The company secured a $250M five-year credit facility, with an initial $75M funded and additional tranches available upon revenue milestones. Q2 2026 financial results will be released on August 11, 2026.
08-03 11:13
